Project Grant R01HL187416
Award Date 9/1/26
Completion Date 4/30/30
Dollars Obligated $814K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irwindale, CA 91010, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Southern California $240,206 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, to engineer therapeutically programmed monocytes that adaptively immunomodulate the post-infarction myocardial microenvironment toward cardiac repair and regeneration. The award funds development of smart monocytes using synnotch receptor circuits that detect inflammation and respond by secreting...
- The National Heart, Lung, and Blood Institute awarded Beckman Research Institute of The City of Hope $697,806 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrative machine learning approaches that decode cardiomyocyte subtype dynamics in heart failure progression. The research addresses molecular mechanisms governing the transition from adaptive cardiac hypertrophy to pathological heart failure. The recipient will generate and analyze...
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $1.379 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardioprotective mechanisms of Y RNA signaling in macrophages as a potential therapeutic approach to myocardial infarction. The research dissects how a small non-coding RNA called YREX3—secreted by therapeutically-enhanced cardiac stromal cells—signals macrophages to enhance their capacity for...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Sanford Burnham Prebys Medical Discovery Institute $1,603,648 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a single-construct gene therapy for enhanced cardiac repair. The funded research aims to overcome barriers to cardiac reprogramming by creating a gene therapy that simultaneously induces overexpression of cardiac transcription factors MEF2C, GATA4, and TBX5 (MGT)...
- The National Heart, Lung, and Blood Institute awarded Duke University $160,040 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 30, 2025, to investigate the ability of an injectable polypeptide scaffold to improve patient outcomes after myocardial infarction. The research focuses on partially ordered polypeptides (POPS), a biomaterial that transitions from an injectable liquid at room temperature to a physically crosslinked, porous network at body temperature. POPS...
- The National Heart, Lung, and Blood Institute awarded Weill Medical College of Cornell University $818,022 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize endothelin-1 (ET-1) and its receptor (ET-RA) as cardiomyocyte proliferation inhibitors in neonatal mice. The research aims to identify mechanisms by which extracellular inhibitory factors suppress heart cell proliferation, with the long-term goal of enabling therapeutic strategies to...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $632,081 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop conformation-sensitive platelet-hitchhiking lipid nanoparticles for targeted delivery of mRNA and small interfering RNA to infarcted heart tissue following myocardial infarction. The project addresses therapeutic limitations in post-infarction recovery by engineering lipid nanoparticles to...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $1,619,582 to the University of Virginia on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cardio-splenic axis in acute myocardial infarction and post-MI heart failure. The project examines the immunopathological mechanisms by which plasmacytoid dendritic cells orchestrate post-MI inflammation and cardiac dysfunction. The research team...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $759,670 on August 11, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate metabolite-driven epigenetic regulation in cardiac repair following myocardial infarction. The research examines how disruptions in metabolic pathways deplete critical metabolites—including acetyl-CoA and α-ketoglutarate—required for epigenetic and RNA-modifying enzymes. The project...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $246,750 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate fibrotic signatures after regenerating and non-regenerating myocardial infarction. The funded research investigates cardiac fibrosis—the deposition of extracellular matrix components in the heart following myocardial injury. While early fibrosis can be protective after myocardial...